Positive Topline Results for SEQUOIA-HCM Trial in OHCM Positive Topline Results for SEQUOIA-HCM Trial in OHCM

Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Source Type: news